Recently, our group and others identified the loss-of-function CYP2C19*2 variant (rs4244285) as a major determinant of clopidogrel response as measured by ADP-stimulated Background-Aspirin or dual antiplatelet therapy with aspirin and clopidogrel is a standard therapy for patients who are at increased risk for cardiovascular events. However, the genetic determinants of variable response to aspirin (alone and in combination with clopidogrel) are not known.
A spirin or dual antiplatelet therapy (DAPT) with aspirin and clopidogrel is standard care for patients who are at increased risk for cardiovascular events. For patients with acute coronary syndrome and undergoing percutaneous coronary intervention (PCI), DAPT is effective in reducing recurrent cardiovascular events.
1,2 However, interindividual variation in platelet response to aspirin, alone or in combination with clopidogrel, has been well documented, 3, 4 and patients who demonstrate higher on-treatment platelet reactivity on DAPT have an increased risk of experiencing an ischemic event. [5] [6] [7] [8] [9] Although the causes of interindividual variability in response to DAPT are multifactorial, 10 the determinants of most of this variation remain unknown.
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platelet aggregation. [11] [12] [13] [14] [15] [16] Although this variant accounts for ≈12% of the variation in inhibition of ADP-stimulated platelet aggregation by clopidogrel and is associated with an ≈1.5-to 2-fold risk of recurrent cardiovascular events in PCI patients, most of the variation potentially attributable to genetics remains unknown. For aspirin response, alone or in combination with clopidogrel, many genes have been examined 10, [17] [18] [19] ; however, few if any have been reproducibly shown to be associated with response. In an attempt to identify the genetic determinants of platelet aggregation in response to aspirin in the setting of DAPT, we measured collagen-stimulated ex vivo platelet aggregation at baseline, after clopidogrel administration, and after clopidogrel and aspirin administration in 565 healthy subjects of the Pharmacogenomics of Anti-Platelet Intervention (PAPI) Study and conducted a genome-wide association study (GWAS). Significant findings in this group were replicated and extended by examining the relation between genotype and cardiovascular outcomes in 2 independent populations: 227 patients recruited from a cardiac catheterization laboratory at Sinai Hospital in Baltimore, MD, and 1000 patients of the International Verapamil SR/Trandolapril Study (INVEST) Genetic Substudy (INVEST-GENES).
Methods

Study Populations
The Amish PAPI Study (NCT0079936) recruited 668 healthy white individuals 20 years of age or older and has been described in detail previously. 11 This report includes 565 PAPI Study subjects who completed the intervention and in whom a complete set of validated collagen-stimulated platelet aggregation tests were available. Further information on this cohort can be found in the online-only Data Supplement. Briefly, platelet-rich plasma was isolated from blood samples of participants, and baseline platelet function was assessed by optical aggregometry with a PAP8E Aggregometer (Bio/Data Corp, Horsham, PA) after stimulation with collagen (5 μg/mL).
11
Participants were then given a 300-mg loading dose of clopidogrel followed by 75 mg/d for 6 days. One hour after the last dose of clopidogrel, platelet aggregation measurements were repeated. To measure aspirin response in the presence of clopidogrel, platelet aggregation was measured later the same day, 1 hour after a single dose of aspirin (324 mg).
The Sinai Hospital of Baltimore Study (NCT00370045) enrolled 227 patients >18 years who were undergoing nonemergent PCI. Characteristics of these patients have been described previously. 11 Of the enrolled patients, 140 (61.7%) were white, 83 (36.6%) were black, and 4 (1.8%) were of other race/ethnicity. Immediately before the PCI, patients received either a 600-mg (n=112) or a 300-mg (n=25) loading dose of clopidogrel; 90 patients were already receiving maintenance therapy with a 75-mg daily dose at the time of PCI and received no loading dose. Patients also received 81 to 325 mg aspirin daily for at least 1 week before PCI and 325 mg on the day of the procedure. Platelet aggregation was assessed in platelet-rich plasma after stimulation with 2 μg/mL collagen with a Chronolog Lumi-Aggregometer (model 490-4D; Chronolog, Havertown, PA), as described previously. 8 Further information on this cohort can be found in the online-only Data Supplement.
Patients were contacted at the end of 1 and 12 months after PCI to determine the occurrence of postdischarge cardiovascular ischemic events. A physician blinded to the study results of the patients adjudicated all end points by reviewing source documents obtained from medical records. Postdischarge ischemic events were defined as myocardial infarction (MI; the occurrence of ischemic symptoms and a troponin I value greater than the upper limits of normal), ischemic stroke, stent thrombosis (definite stent thrombosis according to the Academic Research Consortium criteria), unplanned target vessel revascularization (revascularization of vessel treated at the time of study enrollment), hospitalization for coronary ischemia with revascularization (hospitalization for chest pain with evidence of ischemia on ECG and no evidence of MI as measured by troponin I values), and death secondary to any cardiovascular cause.
The INVEST-GENES study has previously been described. 20 Briefly, DNA from 5979 INVEST patients with hypertension and stable coronary artery disease residing in the mainland United States and Puerto Rico was collected. From these samples, a nested case-control group consisting of 361 patients who experienced death, nonfatal MI, or nonfatal stroke and 639 age-, sex-, and race-frequency-matched controls were evaluated. Components of the primary outcome were adjudicated by an independent adjudication committee. 21 Among these patients, 570 participants (56.8%) were white, 154 (15.3%) were black, and 276 (27.5%) were Hispanic. Of these, 499 were taking aspirin (dose unknown) and 501 were not. Further information on this cohort can be found in the online-only Data Supplement.
Study protocols were approved by the respective institutional review boards. Written informed consent was obtained from each participant; participants were compensated for their participation.
Genotype Analysis
Genotyping in the PAPI Study was performed with the Affymetrix GeneChip Human Mapping 500K or 1 M (version 6.0) arrays according to the manufacturer's instructions (Affymetrix Inc, Santa Clara, CA). Genotype calls were performed with BRLMM (500K array) or Birdseed version 2 (1 M array). Single-nucleotide polymorphisms (SNPs) with minor allele frequencies >1% present on both arrays were included in our analyses. Mean genotype call rate of these 400 230 SNPs was 98.7%. Follow-up genotyping of platelet endothelial aggregation receptor-1 (PEAR1) SNP rs12041331 in the replication/extension cohorts was performed with a TaqMan SNP genotyping assay (Applied Biosystems, Foster City, CA). Genotype concordance rate of this polymorphism in a subset of duplicate samples was 100%.
Statistical Analysis
All Cohorts
Summary statistics and frequencies for the Amish PAPI Study, Sinai Hospital of Baltimore cohort, and INVEST-GENES were generated with SAS version 9.1 (SAS Institute Inc, Cary, NC) or SPSS version 11.5 (Chicago, IL). Because the allele frequency of rs12041331 differed substantially among blacks and whites, we performed all analyses stratified by race. All tests evaluating association with collagen-stimulated platelet aggregation were conducted assuming an additive genetic model. Measures of Hardy-Weinberg equilibrium were calculated with the χ 2 test. For the GWAS, we considered a value of P<5×10 -8 evidence for genome-wide significance. For all other analyses, values of P<0.05 were considered statistically significant.
Amish PAPI Study
Correlates of aspirin response (eg, age, sex, body mass index, lipid levels, and blood pressure) were evaluated with a regression-based approach as implemented in SOLAR version 4.07 (Southwest Foundation for Biomedical Research, San Antonio, TX). Relatedness among study participants was accounted for by the inclusion of a polygenic component as a random effect. Triglyceride levels were logarithm transformed for analysis and back-transformed for presentation. Distribution analyses were generated in SAS. All statistical tests were 2-sided.
Genome-wide association analyses between SNPs and collagenstimulated platelet aggregation at baseline, after clopidogrel, and after both clopidogrel and aspirin treatment were performed under a variance component model that assesses the effect of genotype as an additive effect on the quantitative trait while simultaneously estimating the effects of age, age squared, sex, baseline platelet aggregation (for postclopidogrel and post-clopidogrel and aspirin analyses), and the aforementioned polygenic component. The polygenic component was modeled with the relationship matrix derived from the complete Amish pedigree structure available through the Anabaptist Genealogy Database. 22, 23 Follow-up analyses of SNPs of interest were performed with an additive model. Heritability of baseline platelet aggregation and aspirin response corresponds to the proportion of the trait variance accounted for by the polygenic component. The genomic control λ coefficient was 1.06; thus, the P values reported were unadjusted. To determine whether the PEAR1 SNP rs12041331 accounted for the chromosome 1q23 GWAS signal, we estimated the independent effects of both rs2148135 (the SNP most strongly associated with aspirin response from the genome-wide association analysis) and rs12041331 on platelet aggregation by including both in the model simultaneously.
Power calculations in the PAPI Study population (n=565) indicated 80% power at α=5.0×10 -8 to detect SNPs with minor allele frequencies ranging from 0.2 to 0.4 with effect sizes from 0.43 to 0.35 SD, respectively, accounting for 6% of the phenotypic variation. Pairwise linkage-disequilibrium (LD) statistics (D' and r 2 ) were calculated with Haploview version 4.2 (http://www.broadinstitute. org/haploview/).
Sinai Hospital of Baltimore Study
We estimated the effect of PEAR1 SNP rs12041331 genotype on postaspirin collagen-stimulated platelet aggregation under an additive genetic model. The genotype effect was estimated from ANOVA with adjustment for age, sex, race, study, and treatment group (clopidogrel dose and use of eptifibatide).
Survival curves were generated to evaluate 1-year cardiovascular event-free survival between patients with (n=71) and without (n=156) the PEAR1 rs12041331 A-allele. Relative hazard associated with having the A-allele on subsequent ischemic events was calculated from the proportional hazards model and was adjusted for age and sex. Survival analyses based on rs12041331 were performed both with and without collagen-stimulated platelet aggregation included as a mediator variable.
INVEST-GENES
Characteristics of INVEST-GENES participants were compared by rs12041331 genotype with the use of ANOVA for quantitative traits or the χ 2 test for dichotomous traits. Association analyses of rs12041331 genotype on the occurrence of cardiovascular outcomes were calculated with logistic regression. Analyses stratified by aspirin use were also conducted. Interaction terms between rs12041331 genotype and aspirin use for each analysis were calculated. All tests were adjusted for age, sex, body mass index, history of MI, heart failure, diabetes mellitus, and smoking.
Results
Amish PAPI Study
Characteristics of the PAPI participants are shown in the Table. Clopidogrel therapy alone resulted in mildly reduced collagen-induced platelet aggregation compared with baseline (percentage change in maximal aggregation±SD, 17±23%; P<0.001); however, with the addition of aspirin, there was a marked effect (percentage change in maximal aggregation±SD, 73±16%; P<0.001; Figure I in the onlineonly Data Supplement). Poorer DAPT response was associated with increasing age (12 A GWAS of collagen-induced platelet aggregation revealed a cluster of 5 SNPs (rs2148135, rs11264825, rs6696137, rs7534239, and rs1176535) in high LD and in HardyWeinberg equilibrium (P>0.05) spanning ≈1 MB on chromosome 1q23 showing strong association with DAPT response with P<10 -7 ( Figure 1 and Table II in the online-only Data Supplement). These SNPs were not associated with measures of platelet aggregation at baseline, and only nominal evidence of association was observed after clopidogrel treatment alone (P range=2.62×10 -2 -7.58×10 -4 ). No other regions throughout the genome revealed evidence of association with collageninduced platelet aggregation after DAPT treatment that met or exceeded criteria for genome-wide significance (see Table II in the online-only Data Supplement for all SNPs with P<10 -5 ). Rs2148135 lies in a gene-rich region on chromosome 1q23. On the basis of previous publications 19, [24] [25] [26] and reported biological and genetic information on genes in the chromosome 1q23 region involved in platelet function, further SNP genotyping was performed in the PEAR1 gene (rs12041331), which encodes a type 1 membrane receptor important in platelet aggregation. Analyses revealed that rs12041331 (minor allele frequency, 0.10, Hardy Weinberg P>0.05) in intron 1 of PEAR1 was the SNP most highly associated with collagen-induced platelet aggregation after DAPT administration (P=7.66×10 -9 ). This SNP was not associated with baseline platelet aggregation measures (P=0.89) and was only nominally associated with platelet aggregation after clopidogrel alone (P=0.008; Figure 2 ). Despite its distance from rs2148135 (0.91 MB), rs12041331 was in tight LD with the cluster of 1q23 SNPs identified in the GWAS (D'=1.0 and r 2 =0.94 with rs2148135), possibly as a result of extended LD in this young founder population ( Figure 1 ). After the inclusion of the rs12041331 genotype as a covariate, the association of the most strongly associated 1q23 SNP rs2148135 and DAPT response was markedly attenuated (P=4.85×10 -8 without adjustment to P=2.11×10 -4 with adjustment). In PAPI participants with 0, 1, and 2 copies of the rs12041331 minor allele (A), collagen-stimulated platelet aggregation was reduced to 25.0%, 14.6%, and 7.0% of baseline, respectively, in response to DAPT. Rs12041331, present in its heterozygous and homozygous state in 18.3% and 0.9% of the PAPI Study population, respectively, accounted for 5.1% of the total variation in DAPT response (P<0.001). Rs12041331 was not associated with other cardiovascular or metabolic traits, including blood pressure, carotid intima-media thickness, or fasting serum lipid levels (Table III in 
Sinai Hospital of Baltimore Study
Findings in the PAPI Study were extended by examining the relation between rs12041331 genotype and platelet reactivity and cardiovascular outcomes in a group of patients from Sinai Hospital of Baltimore who underwent PCI. Characteristics of these patients are shown in the Table. Given the difference in rs12041331 minor allele between race/ethnicity, stratified analyses were performed. All patients were taking aspirin before and at the time of PCI. Similar to the PAPI Study, increasing copies of the rs12041331 A-allele in aspirin-treated white subjects tended to result in lower
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collagen-induced platelet aggregation (58.5±3.5, 32.0±4.3, and 28.4±3.4 for GG, GA, and AA genotypes, respectively; P=0.05). In aspirin-treated black patients, the frequency of the A-allele of rs12041331 was higher than in whites (0.30 versus 0.12, respectively), and there was no evidence for an association of rs12041331 with platelet aggregation (32.4±3.9, 34.4±4.6, and 24.5±6.6 for GG, GA, and AA genotypes, respectively; P=0.96).
In the Sinai Hospital cohort, A-allele carriers of rs12041331 tended to experience a cardiovascular event more often compared with GG homozygotes in both white (23.1% versus 9.5%; hazard ratio, 2.62; 95% CI, 0.96-7.10; P=0.059) and black (26.7% versus 7.5%; hazard ratio, 3.97; 95% CI, 1.10-14.31; P=0.035) patients after 1 year of follow-up. In an analyses in which the effects of collagen-stimulated platelet aggregation were included as a covariate, attenuation of *For PAPI Study, all participants were withdrawn from prescription and nonprescription medications, vitamins, and supplements 7 days before and for the duration of the study. Participants taking aspirin, antihypertensive, lipid-lowering, and diabetes mellitus medications accounted for <4% of participants.
†Defined as systolic blood pressure >140 mm Hg or diastolic blood pressure >90 mm Hg or taking prescription medication for previously diagnosed hypertension. ‡Logarithm transformed for analysis and back-transformed for presentation. §Defined as LDL cholesterol >160 mg/dL or taking prescription medication for previously diagnosed hypercholesterolemia. ║Self-reported history of smoking cigarette, pipe, or cigar. In addition, the effect of rs12041331 was independent of and additive to the increased risk of cardiovascular events observed in patients carrying the loss-of-function CYP2C19*2 allele, a well-documented determinant of postclopidogrel ADP-stimulated platelet aggregation ( Figure 3 ).
INVEST-GENES Cohort
Characteristics of the INVEST-GENES participants are shown in the Table and in Table IV Figure II in the online-only Data Supplement). Other cardiovascular and metabolic characteristics were similar when compared by rs12041331 genotype, except for heart failure, in which white A-allele carriers had a higher prevalence of heart failure compared with GG homozygotes (19% versus 10%, respectively; P=0.01).
Discussion
In the PAPI Study, we found collagen-stimulated platelet aggregation in response to aspirin in the presence of clopidogrel, the most commonly prescribed DAPT regimen, to be normally distributed with no distinct cutoff by which to define resistance. Our GWAS and subsequent genotyping identified a common intronic SNP in PEAR1 (rs12041331) accounting for 5.1% of the phenotypic variation of platelet response to aspirin in the presence of clopidogrel. These findings were similar in patients of the Sinai Hospital of Baltimore Study, strengthening our confidence in the initial results and demonstrating generalizability to outbred populations with significant atherosclerotic disease.
Given that rs12041331 was not associated with baseline measures of platelet aggregation and that postaspirin measures were associated with genotype even after adjustment for baseline measures, this polymorphism seems to exert a true pharmacogenetic effect. In addition, rs12041331 was only marginally associated with postclopidogrel collageninduced platelet aggregation, suggesting that the strong association in the presence of both clopidogrel and aspirin reflects largely an effect on aspirin response. Although a synergic effect of both antiplatelet agents is possible, another study reported that after 2 weeks of aspirin treatment (81 mg/d), rs12041331 was significantly associated with platelet aggregation in response to several agonists, suggesting that indeed this variant may be relevant in patients treated with aspirin alone. 26 A GWAS meta-analysis of baseline platelet aggregation identified rs12041331 as the SNP most strongly associated with both ADP-and epinephrine-induced platelet aggregation, suggesting a role of this variant in baseline platelet aggregation via pathways other than those mediated by collagen. 25 We measured the effect of rs12041331 on ADP-stimulated platelet aggregation before and after clopidogrel treatment in both PAPI Study participants and PCI patients from Sinai Hospital and found no evidence of an association in either population using this agonist (data not shown). This observation suggests that the effect of rs12041331 on postaspirin platelet aggregation is mediated through collagen receptor pathways, not ADPdependent pathways. 
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It is important to note that rs12041331 may not be the causal variant and may, in fact, be in LD with the true and as-yet unidentified risk variant. Indeed, the genomic region identified by GWAS contained several genes other than PEAR1. However, in addition to conditional analyses performed in this investigation, which provide evidence that rs12041331 accounted for most of the initial GWAS signal, preliminary RNA sequencing (n=2 samples) and Western blot data in our laboratory suggest that of the genes in this region (ie, FCRL1, FCRL2, FCRL3, FCRL4, FCRL5, ETVL3 , ARHGEF11, C1orf92, and PEAR1), only PEAR1 is expressed in platelets (data not shown). It is important to note, however, that rs2148135 showed nominal evidence of association with collagen-stimulated platelet aggregation after adjustment for rs12041331 genotype (P=2.11×10 -4 ). Therefore, we cannot rule out the possibility that other variants in any one or more of the genes at this locus may contribute to differences in aspirin response. Furthermore, exome sequencing of 60 subjects with and without the risk haplotype did not reveal any variants that were more highly associated with postaspirin platelet aggregation than rs2148135 or rs12041331. These data are consistent with the work of Faraday et al 26 in which sequencing of the entire PEAR1 gene in 104 subjects at the extremes of platelet aggregation distribution revealed no variant more strongly associated with platelet aggregation than rs12041331. In addition, these authors observed rs12041331 allele-specific differences in PEAR1 protein expression by Western blot, ELISA, and luciferase reporter assay, potentially suggesting a mechanism to explain the association between this SNP and platelet aggregation/cardiovascular outcomes.
26
The PEAR1 SNP rs12041331 is a common variant in several ethnically diverse populations. In European, Hispanic, and African populations, ≈21%, 38%, and 67% of individuals, respectively, have at least 1 copy of the risk A-allele, which may have potentially important clinical implications. We observed that both white and black PCI patients on DAPT who were rs12041331 A-allele carriers had decreased eventfree survival. Furthermore, our data suggest that differences in genotype-specific event-free survival are influenced by platelet reactivity because analyses that included collagenstimulated platelet aggregation as a mediator variable showed no significant difference in event rates between rs12041331 D) . Postdischarge ischemic events were defined as myocardial infarction (the occurrence of ischemic symptoms and troponin I value greater than the upper limits of normal), ischemic stroke, stent thrombosis (definite stent thrombosis according to the Academic Research Consortium criteria), unplanned target vessel revascularization (revascularization of vessel treated at the time of study enrollment), hospitalization for coronary ischemia with revascularization (hospitalization for chest pain with evidence of ischemia on ECG and no evidence of myocardial infarction as measured by troponin I values), and death secondary to any cardiovascular cause. All analyses were adjusted for age and sex. CI indicates confidence interval; and HR, hazard ratio. GG homozygotes and A-allele carriers in both white and black patients. However, although white PCI patients who carried the A-allele of PEAR1 rs12041331 tended to have lower levels of platelet aggregation compared with GG homozygotes, we did not observe this association in black PCI patients from Sinai Hospital. This is in contrast to previous investigations by Faraday et al 26 and Johnson et al, 25 which suggest that rs12041331 explains a greater amount of variability in platelet aggregation in blacks compared with whites. This apparent discrepancy in findings may be attributed to differences in study design (eg, our study measured aspirin response on the background of clopidogrel therapy), patient population, or inadequate power in our sample. Another limitation of the PCI cohort is the differing regimens of antiplatelet agents received in the acute setting (1-3 days) . However, stratified analyses of acute management did not detect significant effects on the long-term outcomes investigated. Furthermore, adverse bleeding events could not be evaluated, again because of small sample size.
In the INVEST-GENES study, we also observed a significant influence of PEAR1 SNP rs12041331 on cardiovascular outcomes in the presence of aspirin treatment. White rs12041331 A-allele carriers who were taking aspirin were more likely to experience a fatal or nonfatal MI compared with GG homozygotes. This was not observed in the absence of aspirin administration, again suggesting a true pharmacogenomic effect. Interestingly, rs12041331 A-allele carriers on aspirin seemed to have poorer outcomes than A-allele carriers not on aspirin, suggesting that this variant may identify a subgroup of patients in whom aspirin may be contraindicated. Additional studies are required to examine this finding further. No association was observed between rs12041331 and cardiovascular events in aspirin-treated black or Hispanic subjects. However, the power to detect an association was limited by the small number of cases (n<20 for each subgroup).
The rs12041331 A-allele was associated with lower postaspirin collagen-stimulated platelet aggregation and increased cardiovascular events. Because we replicated platelet aggregation measures in the PAPI and Sinai cohorts and cardiovascular events in the Sinai and INVEST cohorts, these findings are unlikely to be statistical artifacts. The biological basis for this seemingly paradoxical finding is unknown. We acknowledge, however, that in some of our analyses the sample sizes of the comparison groups are small and further replication in independent cohorts is warranted. PEAR1 is a type 1 membrane protein expressed in platelets and endothelial cells. Although its function is not fully known, phosphorylation of PEAR1 seems to facilitate α IIb β 3 -mediated platelet-platelet contacts. 24 In addition, Kauskot et al 27 demonstrated the functional role of PEAR1 in platelet activation/aggregation by showing that phosphorylation of this receptor results in PI3K and AKT activation, amplification of α IIb β 3 signaling, extensive platelet degranulation, and irreversible aggregation reactions. It is possible that decreased expression of PEAR1 on platelets (and perhaps endothelial cells), mediated by rs12041331, results in decreased ex vivomeasured platelet aggregation but unstable thrombi in vivo, leading to increased cardiovascular events. Alternatively, although a growing body of evidence demonstrates that rs12041331 strongly influences platelet aggregation, it is possible that differences in cardiovascular outcomes could be the result of rs12041331-mediated effects on the vascular endothelium where PEAR1 is expressed 6-fold higher than in platelets. 24 Finally, it is also possible that 2 different SNPs in partial LD with rs12041331 but in minimal LD with each other may be independently mediating these seemingly paradoxical effects. Detailed biochemical and signaling characterization of PEAR1 is necessary to understand the mechanisms by which this variant exerts its effects.
In summary, we identified a common variant in PEAR1 (rs12041331) that reproducibly influenced collagen-induced platelet aggregation in response to aspirin in the presence of clopidogrel. This finding was replicated in PCI patients on DAPT and extended to include cardiovascular outcomes in this population and in an independent population with stable coronary artery disease treated with aspirin alone. The findings seem to be independent from and additive to the increased risk of cardiovascular events in DAPT-treated PCI patients carrying the loss-of-function CYP2C19*2 variant. Further studies are necessary to define the precise role of PEAR1 genotyping, perhaps in combination with CYP2C19 genotyping, in prescribing the most effective individualized antiplatelet therapy to reduce recurrent cardiovascular events in high-risk patients. 
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CLINICAL PERSPECTIVE
Aspirin is the most commonly used antiplatelet medication in preventing recurrent cardiovascular events in patients with acute coronary syndrome and undergoing percutaneous coronary intervention. Despite its effectiveness in most patients, considerable variability in aspirin response exists, which manifests by differences in on-treatment platelet reactivity and an increase in adverse clinical outcomes in poor responders. Although the cause of this variability is multifactorial, substantial evidence suggests a genetic underpinning. In this investigation, we identified through a genome-wide association analysis a variant in the platelet endothelial aggregation receptor 1 (PEAR1) gene (rs12041331) as a strong determinant of collagen-induced platelet aggregation after aspirin treatment. These results were replicated in a cohort of patients undergoing nonemergent percutaneous coronary intervention and extended to show significant genotype-specific differences in cardiovascular outcomes in 2 independent populations. Surprisingly, the rs12041331 allele that was associated with lower postaspirin collagen-stimulated platelet aggregation also led to increased cardiovascular events. Furthermore, patients with stable coronary artery disease who carried the PEAR1 risk allele and were on aspirin therapy seemed to have poorer outcomes than carriers not on aspirin, potentially suggesting that this variant may identify a subgroup of patients in whom aspirin may be contraindicated. The biological basis for this seemingly paradoxical finding is unknown. Detailed functional characterization of PEAR1 is necessary to understand the mechanisms by which this variant exerts its effects and to define the role of PEAR1 genotyping in prescribing the most effective individualized antiplatelet therapy to reduce recurrent cardiovascular events in high-risk patients.
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SUPPLEMENTARY MATERIAL SUPPLEMENTAL METHODS
Study Populations
Amish and January 2010. This population has been described in detail previously (11) .
Informative relative pairs for estimating heritability using this population consisted of 164 parent-offspring pairs, 286 sibling pairs, 87 avuncular pairs, and 8 first-cousin pairs.
Participants were extensively phenotyped and physical examinations, medical and family histories, anthropometric measures, and blood samples after an overnight fast were States and Puerto Rico were collected. Using these samples, a nested case-control group consisting of 361 patients who experienced the primary outcome (defined as first occurrence of death, nonfatal myocardial infarction, or nonfatal stroke) and 639 age-, sex-, and race-frequency-matched controls were evaluated. Individual components of the primary outcome were also assessed. All components of the primary outcome were adjudicated by an independent adjudication committee (24) . In this sample, 570 (56.8%) participants were Caucasian, 154 (15.3%) were African American, and 276 (27.5%) were
Hispanic. Information on race/ethnicity was obtained by self-report. Of these individuals, 499 were taking aspirin (dose unknown) and 501 were not.
All study protocols were approved by the respective institutional review boards at the University of Maryland, Sinai Hospital of Baltimore, and the University of Florida.
Written informed consent was obtained from each participant; participants were compensated for their participation. history of heart failure, and diabetes.
SUPPLEMENTARY TABLES
